Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 14/20 | 0.88 |
| ▸ | LPAR2 | Q9HBW0 | 10/20 | 0.88 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.88 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL27625006 | 1.00 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| Phosphoric Acid Monododecyl Ester SCHEMBL28901475 | 1.00 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| Phosphoric Acid Monododecyl Ester SCHEMBL28901478 | 1.00 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| Phosphoric Acid Monotetradecyl Ester SCHEMBL28595278 | 1.00 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| Trimethylammonium SCHEMBL9189106 | 1.00 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| Trimethylammonium SCHEMBL28027117 | 1.00 | LPAR3 (0.88) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| Hexadecyl Dihydrogen Phosphate SCHEMBL27679691 | 0.98 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| Hexadecyl Dihydrogen Phosphate SCHEMBL28208207 | 0.98 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| Phosphoric Acid Monododecyl Ester SCHEMBL27830856 | 0.98 | LPAR3 (0.84) | LPAR3LPAR2LPAR1LPAR5CYP3A4 | |
| Phosphoric Acid Monododecyl Ester SCHEMBL28481088 | 0.96 | LPAR3 (0.95) | LPAR3LPAR2LPAR1LPAR5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249061-A1 | OLIGOSACCHARIDES, PREPARATION METHOD AND USE THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20070142323-A1 | Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same | AVENTIS PHARMA S.A. (FR) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142323-A1 | Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same | SI, RNASE1, OSTC | LPAR3 725/4885LPAR2 1862/4885LPAR1 1673/4885 |
| US-20100249061-A1 | OLIGOSACCHARIDES, PREPARATION METHOD AND USE THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SI, RNASE1, OSTC | LPAR3 725/4885LPAR2 1862/4885LPAR1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.